ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2009. World Malaria Report. Available at: http://apps.who.int/iris/bitstream/10665/44234/1/9789241563901_eng.pdf. Accessed June 9, 2016.
-
2.
Sylla K, Abiola A, Tine RC, Faye B, Sow D, Ndiaye JL, Ndiaye M, Lo AC, Folly K, Ndiaye LA, Gaye O, 2013. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. BMC Infect Dis 13: 598–607.
-
3.
Briggs M, Arguin PM, 2013. Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria–worldwide, 2010–2012. MMWR Morb Mortal Wkly Rep 62: 5–8.
-
4.
Paczkowski MM, Landman KL, Arguin PM, 2014. Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria, United States, 2008 and 2013. MMWR Morb Mortal Wkly Rep 63: 753–755.
-
5.
Burri C, Ferrari G, Ntuku HM, Kitoto AT, Duparc S, Hugo P, Mitembo DK, Lengeler C, 2014. Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue. Am J Trop Med Hyg 91: 821–823.
-
6.
Jarvis JN, Coltart CE, Pule M, Chiodini PL, Doherty T, 2013. Artemisinin therapy and severe delayed haemolysis. Lancet 382: 180.
-
7.
De Nardo P, Oliva A, Giancola ML, Ghirga P, Mencarini P, Bibas M, Nicastri E, Antinori A, Corpolongo A, 2013. Haemolytic anemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria. Infection 41: 863–865.
-
8.
Corpolongo A, De Nardo P, Ghirga P, Gentilotti E, Bellagamba R, Tommasi C, Paglia MG, Nicastri E, Narciso P, 2012. Haemolytic anemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine. Malar J 11: 91–94.
-
9.
Jauréguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, Biligui S, Ciceron L, Mouri O, Kendjo E, Bricaire F, Vray M, Angoulvant A, Mayaux J, Haldar K, Mazier D, Danis M, Caumes E, Thellier M, Buffet P; French Artesunate Working Group, 2014. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 124: 167–175.
-
10.
Arguin PM, 2014. Case definition: postartemisinin delayed hemolysis. Blood 124: 157–158.
-
11.
Rehman K, Lötsch F, Kremsner PG, Ramharter M, 2014. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. Int J Infect Dis 29: 268–273.
-
12.
Laura R, Phillipe L, Marie-Pierre H; Scientific Study Group for Travel Medicine, 2013. A Case of Hemolytic Anemia after Severe Malaria Successfully Treated with Artesunate. Joint Symposium belgische vereniging voor infectiologie en klinische microbiologie. Available at: http://www.sbimc.org/posters%202013/Abstract5.pdf. Accessed June 9, 2016.
-
13.
Raffray L, Receveur MC, Beguet M, Lauroua P, Pistone T, Malvy D, 2014. Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report. Malar J 13: 398–403.
-
14.
Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, Ansong D, Löhr SJ, Burchard GD, May J, Mordmüller B, Krishna S, Kremsner PG, Cramer JP, 2014. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria–a double-center prospective study. J Infect Dis 209: 1921–1928.
-
15.
Neuman G, Boodhan S, Wurman I, Koren G, Bitnun A, Kirby-Allen M, Ito S, 2014. Ceftriaxone-induced immune hemolytic anemia. Ann Pharmacother 48: 1594–1604.
-
16.
Garratty G, 2010. Immune hemolytic anemia associated with drug therapy. Blood Rev 24: 143–150.
-
17.
Imam SN, Wright K, Bhoopalam N, Choudhury A, 2008. Hemolytic anemia from ceftriaxone in an elderly patient: a case report. J Am Med Dir Assoc 9: 610–611.
-
18.
Kudoh T, Nagata N, Suzuki N, Nakata S, Chiba S, Takahashi T, 1994. Minocycline-induced hemolytic anemia. Acta Paediatr Jpn 36: 701–704.
-
19.
Tran TH, Day NP, Ly VC, Nguyen TH, Pham PL, Nguyen HP, Bethell DB, Dihn XS, Tran TH, White NJ, 1996. Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. Clin Infect Dis 23: 1274–1281.
-
20.
Van den Ende J, Coppens G, Verstraeten T, Van Haegenborgh T, Depraetere K, Van Gompel A, Van den Enden E, Clerinx J, Colebunders R, Peetermans WE, Schroyens W, 1998. Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health 3: 632–639.
-
21.
Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, Mørch K, Foroutan B, Suttorp N, Yürek S, Flick H, 2011. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 17: 771–777.
-
22.
Yansouni CP, Libman MD, 2015. Does post-artesunate delayed haemolysis change practice? Travel Med Infect Dis 13: 122–123.
-
23.
Rolling T, Agbenyega T, Krishna S, Kremsner PG, Cramer JP, 2015. Delayed haemolysis after artesunate treatment of severe malaria: review of the literature and perspective. Travel Med Infect Dis 13: 143–149.
-
24.
Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Bierman WF, Clerinx J, van Veldhuizen CK, de Vries PJ, 2012. Treatment outcome of intravenous artesunate in patients with severe malaria in The Netherlands and Belgium. Malar J 11: 102–112.
-
25.
Eder M, Farne H, Cargill T, Abbara A, Davidson RN, 2012. Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre. Pathog Glob Health 106: 181–187.
-
26.
Caramello P, Balbiano R, De Blasi T, Chiriotto M, Deagostini M, Calleri G, 2012. Severe malaria, artesunate and haemolysis. J Antimicrob Chemother 67: 2053–2054.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 342 | 176 | 9 |
| Full Text Views | 432 | 10 | 0 |
| PDF Downloads | 214 | 10 | 0 |
Development of Delayed Hemolytic Anemia After Treatment with Oral Artemether–Lumefantrine in Two Patients with Severe Falciparum Malaria
Yasuhiro Tsuchido
Yasuhiro Tsuchido
Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan.
Search for other papers by Yasuhiro Tsuchido in
Current site
Google Scholar
PubMed
Search for other papers by Yasuhiro Tsuchido in
Current site
Google Scholar
PubMed
Fukumi Nakamura-Uchiyama
Fukumi Nakamura-Uchiyama
Department of Pathogen, Infection and Immunity, Nara Medical University, Nara, Japan.
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Fukumi Nakamura-Uchiyama in
Current site
Google Scholar
PubMed
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Fukumi Nakamura-Uchiyama in
Current site
Google Scholar
PubMed
Kasumi Toyoda
Kasumi Toyoda
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Kasumi Toyoda in
Current site
Google Scholar
PubMed
Search for other papers by Kasumi Toyoda in
Current site
Google Scholar
PubMed
Moritoshi Iwagami
Moritoshi Iwagami
Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Search for other papers by Moritoshi Iwagami in
Current site
Google Scholar
PubMed
Search for other papers by Moritoshi Iwagami in
Current site
Google Scholar
PubMed
Kentaro Tochitani
Kentaro Tochitani
Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan.
Search for other papers by Kentaro Tochitani in
Current site
Google Scholar
PubMed
Search for other papers by Kentaro Tochitani in
Current site
Google Scholar
PubMed
Koh Shinohara
Koh Shinohara
Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan.
Search for other papers by Koh Shinohara in
Current site
Google Scholar
PubMed
Search for other papers by Koh Shinohara in
Current site
Google Scholar
PubMed
Naokuni Hishiya
Naokuni Hishiya
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Naokuni Hishiya in
Current site
Google Scholar
PubMed
Search for other papers by Naokuni Hishiya in
Current site
Google Scholar
PubMed
Taku Ogawa
Taku Ogawa
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Taku Ogawa in
Current site
Google Scholar
PubMed
Search for other papers by Taku Ogawa in
Current site
Google Scholar
PubMed
Kenji Uno
Kenji Uno
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Kenji Uno in
Current site
Google Scholar
PubMed
Search for other papers by Kenji Uno in
Current site
Google Scholar
PubMed
Kei Kasahara
Kei Kasahara
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Kei Kasahara in
Current site
Google Scholar
PubMed
Search for other papers by Kei Kasahara in
Current site
Google Scholar
PubMed
Yukiteru Ouji
Yukiteru Ouji
Department of Pathogen, Infection and Immunity, Nara Medical University, Nara, Japan.
Search for other papers by Yukiteru Ouji in
Current site
Google Scholar
PubMed
Search for other papers by Yukiteru Ouji in
Current site
Google Scholar
PubMed
Shigeyuki Kano
Shigeyuki Kano
Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Search for other papers by Shigeyuki Kano in
Current site
Google Scholar
PubMed
Search for other papers by Shigeyuki Kano in
Current site
Google Scholar
PubMed
Keiichi Mikasa
Keiichi Mikasa
Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Search for other papers by Keiichi Mikasa in
Current site
Google Scholar
PubMed
Search for other papers by Keiichi Mikasa in
Current site
Google Scholar
PubMed
Tsunehiro Shimizu
Tsunehiro Shimizu
Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan.
Search for other papers by Tsunehiro Shimizu in
Current site
Google Scholar
PubMed
Search for other papers by Tsunehiro Shimizu in
Current site
Google Scholar
PubMed
Masahide Yoshikawa
Masahide Yoshikawa
Department of Pathogen, Infection and Immunity, Nara Medical University, Nara, Japan.
Search for other papers by Masahide Yoshikawa in
Current site
Google Scholar
PubMed
Search for other papers by Masahide Yoshikawa in
Current site
Google Scholar
PubMed
Haruhiko Maruyama
Haruhiko Maruyama
Department of Infectious Diseases, Division of Parasitology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Search for other papers by Haruhiko Maruyama in
Current site
Google Scholar
PubMed
Search for other papers by Haruhiko Maruyama in
Current site
Google Scholar
PubMed
Recently, reports of delayed hemolytic anemia after treatment with artemisinin and its derivatives have emerged. Here we report two cases of delayed hemolytic anemia in a patient with severe falciparum malaria after treatment with oral artemether–lumefantrine (AL). The first patient, a 20-year-old Japanese male student, was diagnosed with falciparum malaria and was administered AL. As having a high parasitemia rate (20.6%) was the only severe malaria criterion met in this case and his general condition was stable, we continued with AL treatment. Despite disappearance of malarial parasites after 4 days of AL administration, a persistent fever remained. On days 13 and 16, a diagnosis of hemolytic anemia was made (lactate dehydrogenase [LDH]: 1,466 U/L, hemoglobin [Hb]: 7.2 g/dL). A blood smear at that time revealed no parasites. He recovered naturally from delayed hemolysis. The second patient, a 27-year-old Japanese female student, was diagnosed with falciparum malaria (parasitemia: 4.5%) and treated initially with oral quinine hydrochloride and doxycycline. The following day, parasitemia increased to 7.9% and oral AL was initiated. She was discharged on day 4 after achieving parasite clearance and afebrility. However, on day 5, fever (body temperature > 38°C) recurred, and on day 11, a diagnosis of hemolytic anemia was made (LDH: 712 U/L, Hb: 8.8 g/dL). A follow-up confirmed that her condition improved gradually. AL treatment of severe malaria can cause delayed hemolytic anemia. Patients should be followed up for up to 4 weeks to detect signs of hemolysis and provide appropriate symptomatic treatment.
Author Notes
Consent for publication: Written informed consent was obtained from the patients for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.
Financial support: This research is supported by grants from Ministry of Health, Labour and Welfare (H25-Iryogijutsu-Shitei-012), and the Emerging/Re-emerging Infectious Diseases Project of Japan (15fk0108046h0003) from Japan Agency for Medical Research and development (AMED).
Authors' addresses: Yasuhiro Tsuchido, Kentaro Tochitani, Koh Shinohara, and Tsunehiro Shimizu, Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan, E-mails: tutti.zero@gmail.com, tochiken@me.com, shinoharakoh@gmail.com, and tsunetak915@yahoo.co.jp. Fukumi Nakamura-Uchiyama, Yukiteru Ouji, and Masahide Yoshikawa, Department of Pathogen, Infection and Immunity, Nara Medical University, Nara, Japan, E-mails: fukumi_nakamura@tokyo-hmt.jp, oujix@naramed-u.ac.jp, and myoshika@naramed-u.ac.jp. Kasumi Toyoda, Naokuni Hishiya, Taku Ogawa, Kenji Uno, Kei Kasahara, and Keiichi Mikasa, Center for Infectious Diseases, Nara Medical University, Nara, Japan, E-mails: toyodakasumi@hotmail.co.jp, hissy22@hotmail.com, t.ogawammx@gmail.com, hello_kenji2004@yahoo.co.jp, kassan@naramed-u.ac.jp, and mikasak1@naramed-u.ac.jp. Moritoshi Iwagami and Shigeyuki Kano, Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, E-mails: miwagami@ri.ncgm.go.jp and kano@ri.ncgm.go.jp. Haruhiko Maruyama, Department of Infectious Diseases, Division of Parasitology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan, E-mail: hikomaru@med.miyazaki-u.ac.jp.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2009. World Malaria Report. Available at: http://apps.who.int/iris/bitstream/10665/44234/1/9789241563901_eng.pdf. Accessed June 9, 2016.
-
2.
Sylla K, Abiola A, Tine RC, Faye B, Sow D, Ndiaye JL, Ndiaye M, Lo AC, Folly K, Ndiaye LA, Gaye O, 2013. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. BMC Infect Dis 13: 598–607.
-
3.
Briggs M, Arguin PM, 2013. Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria–worldwide, 2010–2012. MMWR Morb Mortal Wkly Rep 62: 5–8.
-
4.
Paczkowski MM, Landman KL, Arguin PM, 2014. Update on cases of delayed hemolysis after parenteral artesunate therapy for malaria, United States, 2008 and 2013. MMWR Morb Mortal Wkly Rep 63: 753–755.
-
5.
Burri C, Ferrari G, Ntuku HM, Kitoto AT, Duparc S, Hugo P, Mitembo DK, Lengeler C, 2014. Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue. Am J Trop Med Hyg 91: 821–823.
-
6.
Jarvis JN, Coltart CE, Pule M, Chiodini PL, Doherty T, 2013. Artemisinin therapy and severe delayed haemolysis. Lancet 382: 180.
-
7.
De Nardo P, Oliva A, Giancola ML, Ghirga P, Mencarini P, Bibas M, Nicastri E, Antinori A, Corpolongo A, 2013. Haemolytic anemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria. Infection 41: 863–865.
-
8.
Corpolongo A, De Nardo P, Ghirga P, Gentilotti E, Bellagamba R, Tommasi C, Paglia MG, Nicastri E, Narciso P, 2012. Haemolytic anemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine. Malar J 11: 91–94.
-
9.
Jauréguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, Biligui S, Ciceron L, Mouri O, Kendjo E, Bricaire F, Vray M, Angoulvant A, Mayaux J, Haldar K, Mazier D, Danis M, Caumes E, Thellier M, Buffet P; French Artesunate Working Group, 2014. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 124: 167–175.
-
10.
Arguin PM, 2014. Case definition: postartemisinin delayed hemolysis. Blood 124: 157–158.
-
11.
Rehman K, Lötsch F, Kremsner PG, Ramharter M, 2014. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. Int J Infect Dis 29: 268–273.
-
12.
Laura R, Phillipe L, Marie-Pierre H; Scientific Study Group for Travel Medicine, 2013. A Case of Hemolytic Anemia after Severe Malaria Successfully Treated with Artesunate. Joint Symposium belgische vereniging voor infectiologie en klinische microbiologie. Available at: http://www.sbimc.org/posters%202013/Abstract5.pdf. Accessed June 9, 2016.
-
13.
Raffray L, Receveur MC, Beguet M, Lauroua P, Pistone T, Malvy D, 2014. Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report. Malar J 13: 398–403.
-
14.
Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, Ansong D, Löhr SJ, Burchard GD, May J, Mordmüller B, Krishna S, Kremsner PG, Cramer JP, 2014. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria–a double-center prospective study. J Infect Dis 209: 1921–1928.
-
15.
Neuman G, Boodhan S, Wurman I, Koren G, Bitnun A, Kirby-Allen M, Ito S, 2014. Ceftriaxone-induced immune hemolytic anemia. Ann Pharmacother 48: 1594–1604.
-
16.
Garratty G, 2010. Immune hemolytic anemia associated with drug therapy. Blood Rev 24: 143–150.
-
17.
Imam SN, Wright K, Bhoopalam N, Choudhury A, 2008. Hemolytic anemia from ceftriaxone in an elderly patient: a case report. J Am Med Dir Assoc 9: 610–611.
-
18.
Kudoh T, Nagata N, Suzuki N, Nakata S, Chiba S, Takahashi T, 1994. Minocycline-induced hemolytic anemia. Acta Paediatr Jpn 36: 701–704.
-
19.
Tran TH, Day NP, Ly VC, Nguyen TH, Pham PL, Nguyen HP, Bethell DB, Dihn XS, Tran TH, White NJ, 1996. Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. Clin Infect Dis 23: 1274–1281.
-
20.
Van den Ende J, Coppens G, Verstraeten T, Van Haegenborgh T, Depraetere K, Van Gompel A, Van den Enden E, Clerinx J, Colebunders R, Peetermans WE, Schroyens W, 1998. Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health 3: 632–639.
-
21.
Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, Mørch K, Foroutan B, Suttorp N, Yürek S, Flick H, 2011. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 17: 771–777.
-
22.
Yansouni CP, Libman MD, 2015. Does post-artesunate delayed haemolysis change practice? Travel Med Infect Dis 13: 122–123.
-
23.
Rolling T, Agbenyega T, Krishna S, Kremsner PG, Cramer JP, 2015. Delayed haemolysis after artesunate treatment of severe malaria: review of the literature and perspective. Travel Med Infect Dis 13: 143–149.
-
24.
Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Bierman WF, Clerinx J, van Veldhuizen CK, de Vries PJ, 2012. Treatment outcome of intravenous artesunate in patients with severe malaria in The Netherlands and Belgium. Malar J 11: 102–112.
-
25.
Eder M, Farne H, Cargill T, Abbara A, Davidson RN, 2012. Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre. Pathog Glob Health 106: 181–187.
-
26.
Caramello P, Balbiano R, De Blasi T, Chiriotto M, Deagostini M, Calleri G, 2012. Severe malaria, artesunate and haemolysis. J Antimicrob Chemother 67: 2053–2054.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 342 | 176 | 9 |
| Full Text Views | 432 | 10 | 0 |
| PDF Downloads | 214 | 10 | 0 |